Skip to main content

Table 2 Baseline Echocardiographic Parameters

From: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

 

Trimetazidine

Placebo

LA (mm)

52.6 ± 2.1

51.9 ± 1.7

LVEDD (mm)

63.2 ± 2.1

62.4 ± 1.7

LVESD (mm)

41.1 ± 1.5

39.5 ± 1.3

LVEF (%)

32.3 ± 5.3

32.8 ± 2.3

LV Wall Motion Index Score

1.37 ± 0.2

1.38 ± 0.3

E/A

0.68 ± 0.1

0.64 ± 0.12

  1. Baseline echocardiographic parameters in patients randomized to trimetazidine or placebo. No significant differences in echocardiographic and Doppler measures were found between the two groups at baseline.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840